Report Highlights

Viral Gastroenteritis in the U.S.: Market Overview

The U.S. viral gastroenteritis market, valued at USD 2.84 billion in 2024, covers rotavirus and norovirus vaccines, molecular and rapid enteric diagnostics, and oral rehydration products. Government controls the largest revenue pools: the CDC's Vaccines for Children Program purchases rotavirus vaccine at CDC contract prices for eligible children, while CMS sets Medicare rates for laboratory diagnostics. Private manufacturers lead diagnostic platform development and retail oral rehydration sales.

Policy shaped the current structure. ACIP's 2006 recommendation for Merck's RotaTeq, followed by GSK's Rotarix licensure in 2008, created a two-supplier vaccine category, and national vaccination sharply reduced rotavirus hospitalizations among children under five. Norovirus, responsible for most U.S. foodborne illness outbreaks, still has no licensed vaccine, so diagnostics and oral rehydration carry the category's growth.

Policy-Driven Growth in U.S. Viral Gastroenteritis Demand

Three mechanisms drive demand. First, Section 2713 of the Patient Protection and Affordable Care Act requires non-grandfathered private plans to cover ACIP-recommended vaccines without cost-sharing, removing the out-of-pocket barrier for rotavirus doses in commercially insured infants. Second, Section 1928 of the Social Security Act authorizes the Vaccines for Children Program, which supplies vaccines to roughly half of U.S. children and converts ACIP recommendations into guaranteed purchase volumes.

Third, CPT code 87507 covers gastrointestinal pathogen panels of 12 to 25 targets under the Clinical Laboratory Fee Schedule, which CMS updates under the Protecting Access to Medicare Act of 2014. This reimbursement makes syndromic panels financially viable for hospital laboratories. Each mechanism converts clinical guidance into paid volume: ACA coverage raises vaccine uptake, VFC secures public-sector orders, and fee schedule pricing makes multiplex testing the default in stool workups.

Regulatory Barriers and Compliance Costs

FDA classification is the first barrier. Multiplex GI panels require 510(k) clearance or De Novo authorization under the Federal Food, Drug, and Cosmetic Act, with MDUFA performance goals setting a 90-FDA-day review target for 510(k) decisions. FDA's 2024 final rule on laboratory-developed tests was vacated by a federal court in March 2025, so laboratories can still offer in-house assays under CLIA certification administered by CMS.

Vaccine licensure is slower. A biologics license application under Section 351 of the Public Health Service Act undergoes review at FDA's Center for Biologics Evaluation and Research, with a standard goal of 10 months after a 60-day filing period. Coverage then depends on ACIP recommendation, and Vaccines for Children supply requires CDC contract price negotiations that compress manufacturer margins on rotavirus doses.

Policy-Created Opportunities in U.S. Viral Gastroenteritis

The CDC's Epidemiology and Laboratory Capacity cooperative agreement funds state public health laboratories to conduct enteric pathogen surveillance and sequencing. This creates recurring procurement for multiplex panels and sequencing reagents. Public health laboratory budgets provide steadier volume than episodic hospital tenders.

FDA's Food Traceability Rule under Section 204 of the FDA Food Safety Modernization Act, with compliance now due July 20, 2028, requires produce and shellfish firms to maintain traceability records. This drives demand for norovirus testing across food and environmental samples. A future FDA-licensed norovirus vaccine would also enter ACIP review and Vaccines for Children eligibility, opening the largest public-sector purchasing pool in the category.

Market at a Glance

Leading Market Participants

• Merck & Co.
• GSK
• Moderna
• bioMérieux
• QIAGEN
• DiaSorin
• Becton Dickinson
• Cepheid
• Abbott
• Meridian Bioscience

Regulatory and Policy Environment

Primary legislation includes the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, the Clinical Laboratory Improvement Amendments of 1988 administered by CMS with FDA and CDC, the Patient Protection and Affordable Care Act of 2010, the National Childhood Vaccine Injury Act of 1986 governing the Vaccine Injury Compensation Program, and the FDA Food Safety Modernization Act of 2011. Key compliance requirements include CLIA certification for testing laboratories, 510(k) clearance for molecular panels, biologics licensure for vaccines, and preventive controls and traceability records for food firms.

Upcoming changes include the Food Traceability Rule compliance date of July 20, 2028, and renewed debate over FDA oversight of laboratory-developed tests following the March 2025 court vacatur. HHS replaced ACIP membership in June 2025, adding uncertainty to recommendation timing. Compared with Canada, where the National Advisory Committee on Immunization recommends vaccines but provinces fund purchase, the U.S. Vaccines for Children Program creates a more concentrated federal purchasing channel.

Long-Term Policy Outlook for U.S. Viral Gastroenteritis

The most consequential shift by 2032 will be the regulatory pathway for a norovirus vaccine. Moderna's Phase 3 programme will determine FDA review timing, and ACIP's reconstituted membership will set whether the recommendation qualifies for Vaccines for Children and ACA cost-sharing protection. Either outcome will reshape vaccine revenue, which currently concentrates in two rotavirus suppliers.

On the diagnostics side, the policy direction depends on whether Congress or FDA restores oversight of laboratory-developed tests and whether CMS restructures PAMA-driven fee schedules. Food traceability obligations will keep environmental norovirus testing expanding through 2028. These changes support the 4.8% CAGR forecast, with diagnostics delivering most incremental growth.